Key clinical point : Patients with migraine, migraine with aura (MA), or migraine without aura (MO) faced a significantly higher risk for retinal vascular occlusion.
Major findings: Compared with control individuals without migraine, those with migraine (adjusted hazard ratio [aHR] 1.69; 95% CI 1.57-1.83), MA (aHR 1.77; 95% CI 1.58-1.98), or MO (aHR 1.92; 95% CI 1.64-2.25; P < .001 for all) had a significantly higher risk for retinal vascular occlusion. The risk was, however, reduced in the migraine population that received nonsteroidal anti-inflammatory drugs (aHR 0.19; 95% CI 0.16-0.22), propranolol (aHR 0.73; 95% CI 0.62-0.86), or flunarizine (aHR 0.84; 95% CI 0.76-0.93; P < .001 for all).
Study details: This population-based retrospective cohort study included 628,760 patients with migraine and 628,760 control individuals without migraine.
Disclosures: This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial Center, China Medical University Hospital, and National Science and Technology Council. The authors declared no conflicts of interest.
Source: Ho K-Y, Lin C-D, Hsu T-J, et al. Increased risks of retinal vascular occlusion in patients with migraine and the protective effects of migraine treatment: A population-based retrospective cohort study. Sci Rep. 2024;14:15429 (Jul 4). Doi: 10.1038/s41598-024-66363-9 Source